MedTrace Logo

Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate

NCT01174017 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-02-12

No results posted yet for this study

Summary

This study compares the ability of a new design of brachytherapy seed for prostate seed implants for treatment of prostate cancer to maintain their intended position in the prostate after being deposited. Standard seeds, especially in apical locations, have a tendency to migrate distally in response to muscular forces. AnchorSeeds have a textured coating which is designed to prevent migration. 40 patients who are eligible and suitable for prostate brachytherapy will be randomly assigned to receive either standard seeds or AnchorSeeds.

Conditions

Interventions

RADIATION

Iodine 125 standard loose brachytherapy seeds

radioactivity 0.4 U per seed, prescribed dose 144 Gy

RADIATION

AnchorSeed Iodine 125 brachytherapy prostate implant

activity 0.4 U per seed, prescribed dose 144 Gy

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • British Columbia Cancer Agency

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174017 on ClinicalTrials.gov